The stocks of Sudarshan Pharma Industries Ltd were trading at Rs 44.14 on Friday while its highest price was Rs 53.50 and its lowest was Rs 5.82. The firm’s strategic engagement seeks the creation of new centres, bringing in significant investor interest due to its growth potential.
Sudarshan signed an R&D collaboration deal with Emerge on a three-year agreement. The joint venture involves establishing a formulation centre in Dehradun, Uttarakhand and it is set to start operations sometime in 2025. The deal covers essential aspects such as the partnership’s purpose, initiation and duration, all key in Sudarshan’s quest to augment their R and D capabilities.
On January 15, 2025, SPIL’S Board of Directors authorized the purchase of 300 shares of Cibachem General Trading L.L.C located in Dubai. The proceeds from the sale would be put to use by Cibachem, which was incorporated in 2013, together with the Dubai subsidiary, which has its capital structure entirely debt. Cibachem paid AED 1000. Once the deal is executed, Cibachem will be fully consolidated into SPIL and will be incorporated as a 100% subsidiary of SPIL paid capital.
Another Interesting Development is the sub-division of shares initiated by SPIL’s directors on November 22, 2023, since in Cibachem they owned only one 10 rupees equity share, reducing the overall weight of each equity share to 1 rupee, these changes will lead to a more extensive market and enhance technology equipment. The transaction is expected to be concluded by March 31 2025 and is not related to India’s Foreign Investment Act.
SPIL achieved a market cap that exceeds Rs 1,000 cr alongside profit growth of 37% CAGR in the past 5 years. This firm managed to provide multibagger returns of 658% when the stock rose from its 52-week low of Rs 5.82. Not only this, SPiL boasts stellar financial growth as well, with their profit growth consistently increasing.
A leading manufacturer of generic formulations, SPIL was founded in 2008 and is based in Mumbai. Their clientele is extremely diverse as their operations include but aren’t limited to; Leady Chemicals, Intermediates, API, Pharmaceutical Generics, and Bulk Supplies. SPIL’s Vimac Healthcare division aids the firm in entering the branded products market as they possess 56 out of 96 products registered under the “R” trademark. Additionally, SPIL also offers contract manufacturing services to notable Indian businesses.
SPIL actively tries to enhance the services it provides, an example of this effort is its newly built R&D centre in Dehradun and the Cibachem acquisition. These two additions allow SPIL to innovate further aiding the firm in expanding globally. Moreover, these efforts are key in SPIL maintaining an upward trajectory in both the pharmaceutical and chemical markets.
